Childhood Adversity Linked to Cognitive Impairment in Schizophrenia
People with schizophrenia and cognitive impairment reported significant childhood adversity, especially the lack of parental involvement and family hardships.
Schizophrenia
Better Outcomes in Pediatric-Onset vs Adult-Onset Bipolar Disorder
Individuals with pediatric-onset bipolar disorder fare better than individuals diagnosed at a later age with the disorder, and bipolar disorder in general is associated with better outcomes than schizophrenia.
Familial Risk Plays a Moderate Role in Substance-Induced Psychotic Disorder
Schizophrenia subsequent to substance-induced psychosis is likely a drug-precipitated disorder in highly vulnerable individuals, not a syndrome resulting from drug exposure.
Increased Protein Insolubility May Be Related to Subtype of Schizophrenia
Discovering the molecular mechanism of this subtype of schizophrenia could lead to the identification of novel therapeutic targets.
Leveraging Neuroimaging for the Diagnosis of Psychiatric and Neurodegenerative Diseases
A number of psychiatric and neurodegenerative diseases are associated with abnormal imaging findings, which can help psychiatrists reach a diagnosis.
Leveraging Pharmacogenetic Testing to Improve Treatment Adherence in Mental Illness
Leveraging pharmacogenetics for selecting treatments may benefit patients with treatment-resistant schizophrenia and other psychotic disorders.
Taking Into Account Drug-Drug Interactions When Prescribing Third-Generation Antipsychotics
Psychiatrists need to take into account possible drug-drug interactions when prescribing third generation antipsychotics to their patients with schizophrenia.
Valbenazine and Tetrabenazine Show Promise in Treating Tardive Dyskinesia
Valbenazine and tetrabenazine may represent promising options for the treatment of tardive dyskinesia in patients on long-term antipsychotic medications.
Novel Treatment for Schizophrenia Gets FDA’s Breakthrough Therapy Designation
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to SEP-363856 (Sunovion), an investigational treatment for schizophrenia. SEP-363856 is believed to work by activating trace amine-associated receptor 1 (TAAR1) in addition to 5-HT1A receptors; unlike other antipsychotics, this novel agent does not bind to D2 or 5-HT2A receptors. The Breakthrough Therapy designation was…
Duration of Marriage at Conception May Increase Schizophrenia Risk in Offspring
Offspring born to couples married for less than 3 years have a small increased risk for schizophrenia.
Next post in Schizophrenia and Psychoses
